发明名称 |
NATURAL-KILLER/T-CELL LYMPHOMA (NKTCL) SUSCEPTIBILITY PREDICTION, DIAGNOSIS AND THERAPY |
摘要 |
Natural-Killer T-Cell Lymphoma (NKTCL) susceptibility prediction, diagnosis and therapy. The invention relates to a method for predicting Natural Killer T-cell Lymphoma (NKTCL) susceptibility and/or diagnosing NKTCL in a subject comprising testing for JAK mutations. The invention also relates to a method of screening for candidate agents capable of treating NKTCL using a cell line comprising at least one JAK mutation. The invention includes an NKTCL animal model comprising at least one JAK mutation. The invention also includes JAK inhibitors for treating NKTCL. |
申请公布号 |
US2015292022(A1) |
申请公布日期 |
2015.10.15 |
申请号 |
US201214360804 |
申请日期 |
2012.11.26 |
申请人 |
SINGAPORE HEALTH SERVICES PTE LTD |
发明人 |
Teh Bin Tean;Lim Soon Thye |
分类号 |
C12Q1/68;A61K31/519 |
主分类号 |
C12Q1/68 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method for predicting Natural Killer T-Cell Lymphoma (NKTCL) susceptibility and/or diagnosing NKTCL in a subject, comprising testing for the genotype of said subject for at least one JAK gene or testing for whether said subject expresses a wildtype or mutant JAK protein, wherein the presence of a mutant JAK gene indicates that a subject is at risk of developing and/or has NKTCL. |
地址 |
Singapore SG |